Affiliate disclosure: Care Path Compare may receive financial compensation when you access services through partner links such as Gala Health. Commercial partnerships never compromise our clinical objectivity, pricing verifications, or consumer policy reporting. Hims is evaluated independently as a non-partner benchmark.

Head-to-head overview: Hims vs. Gala Health

When deciding between Hims and Gala Health, the central trade-offs center around medication selection (semaglutide-only vs. semaglutide plus tirzepatide), delivery format (oral vs. subcutaneous injection), and upfront capital requirements.

Comparison Feature Hims Gala Health
Membership Dues $0 separate fee (care bundled into subscription) $0 separate fee (care and medication bundled into package)
Medication Options Compounded semaglutide & oral non-GLP-1 kits Compounded semaglutide & compounded tirzepatide
Compounded Tirzepatide Availability Not offered (semaglutide only) Available across multi-month bundles ($299/mo equiv)
Delivery Formats Subcutaneous injections & oral sublingual tablets Subcutaneous injections (clinical standard)
Compounded Semaglutide Entry Price $199/mo (requires $2,388 12-mo prepay) or $399/mo-to-mo $199/mo ($597 for 3 months) or $179/mo ($2,148 12-mo prepay)
Day-One Upfront Cash Outlay $399 (1 month) or $2,388 (12-month prepay) $597 (3-month bundle) or $2,148 (12-month prepay)
Clinical Consultation Model Asynchronous intake reviewed by licensed providers + app messaging Asynchronous intake reviewed by licensed clinicians; Dr. Joshua Klein
Pharmacy Network BPI Labs (FDA-registered 503B) & licensed 503A partners State-licensed 503A compounding pharmacy partners
Cancellation Notice Window At least 48 hours before next billing date Strict 72 hours before next renewal billing cycle
Refund Policy Non-refundable once pharmacy fulfills prescription No prorated refunds; remaining prepaid months forfeited

Key differences: Breaking down treatments, commitments, and efficacy

1. Medication range: Semaglutide-only vs. dual-action tirzepatide

A crucial differentiator between Hims and Gala Health is the scope of available active pharmaceutical ingredients:

  • Hims’ Single-Incretin Focus: Hims focuses exclusively on semaglutide (a selective GLP-1 receptor agonist). While semaglutide is clinically validated for substantial weight reduction (averaging ~15% in landmark clinical trials), Hims does not offer compounded tirzepatide. If a patient reaches a weight-loss plateau on semaglutide or experiences persistent gastrointestinal intolerance, Hims cannot titrate them to a dual-agonist alternative.
  • Gala Health’s Dual-Incretin Portfolio: Gala Health dispenses both compounded semaglutide and compounded tirzepatide. Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist that demonstrated superior mean weight loss (~20.9% in the SURMOUNT-1 clinical trial) compared to selective GLP-1 monotherapy. Having access to both compounds allows patients to select the clinical profile that best fits their weight loss goals and tolerability.

2. Oral tablets vs. subcutaneous injections (The bioavailability reality)

Hims heavily markets oral weight-loss options, making the format comparison critical for consumers:

  • Oral Peptides and Bioavailability: Oral compounded semaglutide tablets must survive stomach acid, digestive enzymes, and liver first-pass metabolism. Without specialized absorption enhancers (like the SNAC technology found in branded Rybelsus), peptide absorption through the gastrointestinal tract is extremely inefficient (typically less than 1% bioavailability). Many consumers choose oral drops or tablets hoping to avoid needles, only to experience suboptimal appetite suppression.
  • Subcutaneous Injections: Both Gala Health and Hims offer subcutaneous injections. Injected semaglutide and tirzepatide enter the bloodstream directly, achieving approximately 100% systemic bioavailability. Gala Health exclusively dispenses injectable formulations to ensure patients receive clinically validated therapeutic drug concentrations.

3. Upfront cash commitments: $2,388 vs. $597 entry barriers

Both platforms advertise low monthly equivalent prices, but their upfront payment requirements differ substantially:

  • Hims Pricing Structure: Hims promotes compounded semaglutide starting at “$199/month.” However, locking in this $199 rate requires paying $2,388 upfront on day one for an entire 12-month package. If you prefer to pay month-to-month, Hims charges $399 per month. Hims also offers a 3-month package at $299/month ($897 upfront) and a 6-month package at $249/month ($1,494 upfront).
  • Gala Health Pricing Structure: Gala Health offers a 3-month semaglutide bundle at $199/month ($597 billed upfront). To achieve Gala’s lowest semaglutide rate of $179/month, patients prepay $2,148 for 12 months. For compounded tirzepatide, Gala offers a 3-month bundle at $299/month ($897 upfront).

For a patient seeking a 3-month injectable semaglutide trial, Gala Health requires $597 upfront, whereas Hims requires $897 upfront (or $1,197 if paying Hims’ $399 month-to-month rate for three months).

4. Compounding pharmacy sourcing: 503B vs. 503A

Pharmacy models represent a notable regulatory distinction between the two companies:

  • Hims 503B Sourcing: Hims has established high-volume sourcing partnerships with FDA-registered Section 503B outsourcing facilities, notably BPI Labs, in addition to state-licensed 503A pharmacies. 503B facilities are subject to current Good Manufacturing Practice (cGMP) regulations and direct FDA facility inspections, compounding batches without requiring individual patient-specific prescriptions upfront.
  • Gala Health 503A Network: Gala Health works through state-licensed Section 503A compounding pharmacies. In 503A compounding, each prescription is filled specifically for an individual patient following clinician review. Partner facilities adhere to USP <797> sterile compounding standards, though Gala does not disclose the specific dispensing pharmacy prior to shipment.

Financial comparison across 3, 6, and 12 months

Here is how out-of-pocket costs compare between Hims and Gala Health for injectable compounded semaglutide.

Treatment Duration Hims (Month-to-Month) Hims (Prepaid Commitment) Gala Health (Prepaid Bundles) Lowest Total Outlay
Month 1 (Day 1) $399 $897 (3-mo plan) / $2,388 (annual) $597 (covers Months 1–3) Gala saves $300 vs Hims 3-mo plan
3 Months $1,197 ($399 × 3) $897 ($299/mo plan) $597 total ($199/mo equivalent) Gala saves $300 to $600
6 Months $2,394 ($399 × 6) $1,494 ($249/mo plan) $1,194 total (two 3-mo bundles) Gala saves $300 to $1,200
12 Months $4,788 ($399 × 12) $2,388 ($199/mo annual prepay) $2,148 total (one 12-mo prepay) Gala saves $240 to $2,640

Note: Published self-pay rates as of October 2026. Assumes continuous injectable semaglutide treatment.

How to choose between Hims and Gala Health

Choose Gala Health if:

  1. You want access to compounded tirzepatide, which is not available through Hims.
  2. You want the lowest 3-month entry cost for injections ($597 total at $199/mo vs. Hims’ $897 for 3 months).
  3. You want the lowest annual cost for semaglutide ($2,148 annual prepay vs. Hims’ $2,388).
  4. You prefer subcutaneous injections over low-bioavailability oral peptide drops or tablets.

Choose Hims if:

  1. You strongly prefer oral weight-loss medications over weekly self-injections.
  2. You value brand prestige and app technology, preferring a publicly traded company (NYSE: HIMS) with integrated mobile messaging.
  3. You prefer 503B outsourcing facility sourcing (BPI Labs) with cGMP manufacturing standards.
  4. You want a 48-hour cancellation notice window rather than Gala’s 72-hour cutoff rule.